Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
0.8124
-0.0976 (-10.73%)
At close: Mar 13, 2026, 4:00 PM EDT
0.7962
-0.0162 (-1.99%)
After-hours: Mar 13, 2026, 7:36 PM EDT
Citius Oncology Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Citius Oncology stock has a target of 6.00, which predicts a 638.55% increase from the current stock price of 0.81.
Price Target: $6.00 (+638.55%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 23, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Citius Oncology is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $6 | Hold → Strong Buy | Upgrades | $6 | +638.55% | Sep 23, 2025 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 23, 2025 |
| Maxim Group | Maxim Group | Strong Buy Initiates $3 | Strong Buy | Initiates | $3 | +269.28% | Nov 27, 2024 |
| EF Hutton | EF Hutton | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +638.55% | Aug 13, 2024 |
Financial Forecast
Revenue This Year
39.65M
Revenue Next Year
121.32M
from 39.65M
Increased by 205.99%
EPS This Year
-0.19
from -0.34
EPS Next Year
0.40
from -0.19
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 40.8M | 124.9M | |
| Avg | 39.6M | 121.3M | |
| Low | 38.1M | 116.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | 215.0% | |
| Avg | - | 206.0% | |
| Low | - | 194.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.20 | 0.41 | |
| Avg | -0.19 | 0.40 | |
| Low | -0.19 | 0.38 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.